17 / 27
Long-term survival benefit by histology and
PD-L1 expression subgroups
IC, tumor-infiltrating immune cells; TC, tumor cells. Data cutoff: 23 January, 2017.
TC3 or IC3 = TC ≥ 50% or IC ≥ 10% PD-L1+; TC2/3 or IC2/3 = TC or IC ≥ 5% PD-L1+; TC1/2/3 or IC1/2/3 = TC or IC ≥ 1% PD-L1+; TC0 and IC0 = TC and IC < 1% PD-L1+.
Satouchi, et al. WCLC 2017
17
0
10
20
30
40
0
10
20
30
40
0
10
20
30
40
2-year OS Rate (%)
TC0 and IC0
(n = 180)
(n = 199)
Squamous
(n = 112)
(n = 110)
TC3 or IC3
(n = 72)
(n = 65)
TC2/3 or IC2/3
(n = 129)
(n = 136)
TC1/2/3 or
IC1/2/3
(n = 241)
(n = 222)
Atezolizumab
Docetaxel
35%
20%
43%
35%
32%
30%
24%
12%
17%
23%
24%
18%
31%
21%
ITT
(n = 425)
(n = 425)
Non-squamous
(n = 313)
(n = 315)